Tesofensine vs Chonluten
Side-by-side comparison of key properties, dosing, and research.
Fat Loss & Metabolic
TesofensineAnti-Aging & Longevity
Chonluten- Summary
- Tesofensine is a triple monoamine reuptake inhibitor (TMRI) that blocks reuptake of serotonin, dopamine, and norepinephrine. Originally developed for Alzheimer's and Parkinson's disease, it was repurposed as a potent weight loss agent after clinical trials demonstrated substantial fat loss via appetite suppression and increased energy expenditure.
- Chonluten is a tripeptide bioregulator (Glu-Asp-Leu) developed by Professor Vladimir Khavinson, tissue-specific to the bronchi and lungs. While related to Bronchogen (a tetrapeptide), Chonluten is a shorter tripeptide sequence. It supports bronchial mucosal cell function, promotes respiratory epithelial regeneration, and is used in protocols for COPD, chronic bronchitis, and pulmonary anti-aging.
- Half-Life
- 8-10 days (exceptionally long; accumulates over weeks)
- Short (minutes for the peptide); sustained gene-regulatory effects
- Admin Route
- Oral
- SubQ, Oral
- Research
- —
- —
- Typical Dose
- 0.25-0.5 mg per day
- 10 mg per day
- Frequency
- Once daily
- Daily for 10–30 days
- Key Benefits
- Potent appetite suppression via triple monoamine reuptake inhibition
- Significant weight loss (8-12% body weight in phase II trials at 0.5 mg)
- Increases basal metabolic rate and energy expenditure
- Reduces fat mass preferentially over lean mass
- Potential cognitive benefit via dopaminergic and noradrenergic enhancement
- Longer half-life than sibutramine allows once-daily dosing
- Supports bronchial mucosal regeneration and repair
- May improve mucociliary clearance in chronic respiratory conditions
- Anti-inflammatory effects on bronchial epithelium
- Pulmonary anti-aging and tissue preservation
- Supports lung function in COPD and chronic bronchitis
- Well tolerated in combination with other Khavinson bioregulators
- Short tripeptide with efficient cellular penetration
- Side Effects
- Elevated heart rate and blood pressure (sympathomimetic)
- Dry mouth
- Insomnia and sleep disturbances
- Nausea
- +4 more
- Generally well tolerated
- Mild injection site reactions possible
- No significant adverse pulmonary events reported
- Stacks With
- —
- —